High affinity nerve growth factor receptor: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 30: | Line 30: | ||
**[[5kvt]], [[5wr7]] – hTrkA kinase domain + anticancer drug<br /> | **[[5kvt]], [[5wr7]] – hTrkA kinase domain + anticancer drug<br /> | ||
**[[4aoj]], [[4pmm]], [[4pmp]], [[4pms]], [[4pmt]], [[4yne]], [[4yps]], [[5h3q]], [[6dkb]], [[6dkg]], [[6dki]], [[6dkw]], [[6j5l]], [[6npt]], [[6nsp]], [[6nss]] - hTrkA kinase domain + inhibitor<br /> | **[[4aoj]], [[4pmm]], [[4pmp]], [[4pms]], [[4pmt]], [[4yne]], [[4yps]], [[5h3q]], [[6dkb]], [[6dkg]], [[6dki]], [[6dkw]], [[6j5l]], [[6npt]], [[6nsp]], [[6nss]], [[6iqn]], [[6pl1]], [[6pl2]], [[6pl3]], [[6pl4]] - hTrkA kinase domain + inhibitor<br /> | ||
**[[5kmj]], [[5kmk]], [[5kml]], [[5kmm]], [[5kmn]], [[5kmo]], [[6d1y]], [[6d1z]], [[6d20]], [[5i8a]], [[5jfs]], [[5jfv]], [[5jfw]], [[5jfx]], [[5kmi]], | **[[5kmj]], [[5kmk]], [[5kml]], [[5kmm]], [[5kmn]], [[5kmo]], [[6d1y]], [[6d1z]], [[6d20]], [[5i8a]], [[5jfs]], [[5jfv]], [[5jfw]], [[5jfx]], [[5kmi]], [[6pma]], [[6pmb]], [[6pmc]], [[6pme]] – hTrkA catalytic+juxtamembrane domains 376-698 + inhibitor <br /> | ||
**[[2ifg]] – hTrkA nerve growth factor-binding domain + nerve growth factor <br /> | **[[2ifg]] – hTrkA nerve growth factor-binding domain + nerve growth factor <br /> | ||
}} | }} | ||
Revision as of 09:42, 18 August 2020
FunctionHigh affinity nerve growth factor receptor (TrkA) is a tyrosine kinase receptor. Trk stands for Topomyosin-Related Kinase. TrkA ligand - nerve growth factor activates the receptor by stabilizing homodimer formation which initiates transautophosphorylation[1]. See also Neurotrophin. RelevanceTrkA has a role in the pathogenesis of psoriasis and its inhibitors are studied in the development of novel therapeutics for the disease[1]. TrkA inhibition may be a novel therapeutic approach to Alzheimer disease[2] and a new method to treat intractable pain[3]. Structural highlights. An , conserved in all neutrophins, forms the most important binding determinant between TrkA and its ligand - nerve growth factor - which forms the active homodimer of the receptor[4], [5]. .
|
| ||||||||||
3D structures of high affinity nerve growth factor receptor3D structures of high affinity nerve growth factor receptor
Updated on 18-August-2020
ReferencesReferences
- ↑ 1.0 1.1 Gill JS, Windebank AJ. Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion. Neuroscience. 1998 Dec;87(4):855-60. PMID:9759973
- ↑ Zhang Q, Descamps O, Hart MJ, Poksay KS, Spilman P, Kane DJ, Gorostiza O, John V, Bredesen DE. Paradoxical effect of TrkA inhibition in Alzheimer's disease models. J Alzheimers Dis. 2014;40(3):605-617. doi: 10.3233/JAD-130017. PMID:24531152 doi:http://dx.doi.org/10.3233/JAD-130017
- ↑ Hirose M, Kuroda Y, Murata E. NGF/TrkA Signaling as a Therapeutic Target for Pain. Pain Pract. 2016 Feb;16(2):175-82. doi: 10.1111/papr.12342. Epub 2015 Aug 27. PMID:26452158 doi:http://dx.doi.org/10.1111/papr.12342
- ↑ Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. PMID:17196528 doi:10.1016/j.neuron.2006.09.034
- ↑ Wiesmann C, Ultsch MH, Bass SH, de Vos AM. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature. 1999 Sep 9;401(6749):184-8. PMID:10490030 doi:10.1038/43705